European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm
Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis…
Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis…
An antibody that blocks the action of a hidden viral protein encoded by our genome…
GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in…
The FDA has awarded Orphan Drug Designation to GeNeuro's antibody for the treatment of a…
A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in…
Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United…
With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis.…
GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company's CFO, who…
We last wrote about GeNeuro in January, when they announced the launch of an IPO…
GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought…